Article
Pharmacology & Pharmacy
Kumar Ganesan, Bing Du, Jianping Chen
Summary: Breast cancer is the most frequently diagnosed cancer among females globally, and the need for effective therapy is crucial. This review focuses on the potential therapeutic role of dietary bioactive compounds in the prevention and treatment of breast cancer, as they have shown promising effects with minimal side effects.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Nutrition & Dietetics
Kholoud K. Khoja, Melanie-Jayne R. Howes, Robert Hider, Paul A. Sharp, Iain W. Farrell, Gladys O. Latunde-Dada
Summary: Trigonella foenum-graecum L., commonly known as fenugreek, is a promising plant that contains bioactive compounds with potential anti-cancer effects. This study evaluated the cytotoxic and antiproliferative activities of fenugreek seeds and sprouts in breast cancer cells and identified several flavones and isoflavones in the extracts. The results showed that the fenugreek extracts had dose- and time-dependent effects on cell viability and also increased DNA damage and suppressed metastasis and proliferation in the cancer cells. Fenugreek sprouts were identified as an untapped resource for bioactive compounds.
Review
Nutrition & Dietetics
Chandra K. Singh, Gagan Chhabra, Arth Patel, Hao Chang, Nihal Ahmad
Summary: Studies have shown the importance of zinc in prostate biology and functions, with high concentrations in healthy prostates and decreased levels in prostate cancer. Zinc supplementation may not effectively increase zinc concentrations in PCa, possibly due to dysregulation of zinc transporters. Natural dietary phytochemicals may modulate zinc levels and combined with zinc, could potentially inhibit prostate cancer.
Article
Biochemistry & Molecular Biology
Violet A. Kiesel, Silvia D. Stan
Summary: Notch signaling plays a crucial role in cancer development and targeting this pathway has potential therapeutic benefits. In addition to pharmaceutical agents, dietary and natural agents have been explored as alternative approaches to modulating Notch signaling. Certain dietary agents have been found to regulate Notch pathway components in different types of cancer, leading to reduced cell viability and tumor growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yuchong Peng, Rong Tang, Liuyang Ding, Rirong Zheng, Youhong Liu, Linglong Yin, Yongming Fu, Tanggang Deng, Xiong Li
Summary: In this study, a potentially effective component, diosgenin (DSG), was identified from traditional Chinese medicine (TCM) for the treatment of prostate cancer (PCa) by using network pharmacology and molecular docking. DSG specifically targeted UHRF1 protein and induced its degradation through the ubiquitin-proteasome pathway. DSG reduced DNA methylation and increased the expression of tumor suppressor genes, resulting in cell cycle arrest, cellular senescence, and inhibition of tumor growth. This study revealed a novel anticancer mechanism of DSG and provided a promising strategy for discovering new molecule-targeted drugs from small-molecule natural products.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Oncology
Daniela Carreno, Nestor B. Corro, Javier F. Cerda-Infante, Carolina E. Echeverria, Catalina A. Asencio-Barria, Veronica A. Torres-Estay, Gonzalo A. Mayorga-Weber, Pablo A. Rojas, Loreto P. Veliz, Pedro A. Cisternas, Viviana P. Montecinos, Ignacio F. San Francisco, Manuel A. Varas-Godoy, Paula C. Sotomayor, Maite A. Castro, Francisco J. Nualart, Nibaldo C. Inestrosa, Alejandro S. Godoy
Summary: Prostate cancer cells overexpress fructose transporters compared with benign cells, and fructose can stimulate proliferation and invasion of prostate cancer cells. This study suggests that fructose may serve as an alternative energy source for prostate cancer cells, promoting their growth and aggressiveness both in vitro and in vivo.
Article
Biochemistry & Molecular Biology
Joell L. Solan, Sunil R. Hingorani, Paul D. Lampe
Summary: Pancreatic ductal adenocarcinoma (PDA) is characterized by aggressive nature, high metastasis, and strong desmoplasia. Connexin protein Cx43 plays a crucial role in regulating PDA progression through modulation of cell behaviors and gap junction assembly. Mutation in Cx43 phosphorylation sites can significantly impact cancer progression, leading to extended lifespan and reduced metastasis in mouse models. Moreover, stromal gap junctions and associated signaling events mediated by Cx43 may facilitate the metastatic capacity of primary tumors.
Article
Pharmacology & Pharmacy
Pukar Khanal, Vishal S. Patil, Vishwambhar V. Bhandare, Priyanka P. Patil, B. M. Patil, Prarambh S. R. Dwivedi, Kunal Bhattacharya, Darasaguppe R. Harish, Subarna Roy
Summary: The aim of this study was to investigate the mechanism of action of diosgenin against breast cancer using system biology tools and experimental validation. Diosgenin-regulated domains associated with breast cancer were identified and diosgenin-protein-pathway associations were established. Molecular docking and dynamics simulations confirmed the binding affinity of diosgenin with key proteins, and functional assays validated its effects on cell proliferation, cytotoxicity, and the Warburg effect.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Nicole Ramos-Solis, Tinslee Dilday, Alex E. Kritikos, Elizabeth S. Yeh
Summary: HUNK, a protein kinase related to breast tissue, has been shown to play a significant pathogenic role in breast cancer. Inhibiting HUNK can suppress tumor growth and metastasis.
Review
Engineering, Biomedical
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Summary: Management of aggressive breast cancer, particularly TNBC, remains challenging despite advances in treatment. New therapies like atezolizumab, olaparib, and sacituzumab show limited survival benefits. Current research aims to improve treatment strategies by enhancing bioavailability, targetability, and reducing toxicity for better therapeutic outcomes.
BIOACTIVE MATERIALS
(2021)
Article
Chemistry, Multidisciplinary
Shengyong Geng, Xianbin Zhang, Tingting Luo, Mingyang Jiang, Chenchen Chu, Lie Wu, Peng Gong, Wenhua Zhou
Summary: This study developed a novel combination chemotherapy strategy based on bioactive black phosphorus and gemcitabine for efficient treatment of pancreatic cancer. The combination of black phosphorus and gemcitabine induced synergistic killing of pancreatic cancer cells by blocking different phases of the cell cycle. The targeted nanoplatform BP-GEM@NPs demonstrated excellent tumor targeting capability and prolonged blood circulation time, leading to enhanced apoptosis of pancreatic tumor cells and inhibiting tumor growth.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Pharmacology & Pharmacy
Sakshi Sikka, Muthu K. Shanmugam, Kodappully Sivaraman Siveen, Tina H. Ong, Min Hee Yang, Jong Hyun Lee, Peramaiyan Rajendran, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Shireen Vali, Alan Prem Kumar, Gautam Sethi, Lingzhi Wang, Kam Man Hui, Kwang Seok Ahn
Summary: Research has shown that diosgenin can inhibit the activation of NF-Kappa B/STAT3 in prostate cancer cells and suppress tumor progression in in vivo models. This inhibition is achieved through the suppression of protein kinases and reporter gene activity, leading to reduced expression of tumorigenic gene products.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Oncology
Jun Hao, Xinpei Ci, Yong Wang, Stephen Yiu Chuen Choi, Sarah E. Sullivan, Hui Xue, Rebecca Wu, Xin Dong, Anne M. Haegert, Colin C. Collins, Dong Lin, Yuzhuo Wang
Summary: The study revealed a reciprocal feedback between GRB10 and AR signaling, indicating the importance of GRB10 in the progression of prostate cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Macarena Lozano-Lorca, Margarita Rodriguez-Gonzalez, Inmaculada Salcedo-Bellido, Fernando Vazquez-Alonso, Miguel Arrabal, Benita Martin-Castano, Maria-Jose Sanchez, Jose-Juan Jimenez-Moleon, Rocio Olmedo-Requena
Summary: This study evaluated the role of dietary patterns on prostate cancer (PCa) by tumor aggressiveness and extension. It found that an unhealthy dietary pattern was associated with higher odds of PCa, especially for cases with ISUP 1-2 and localized PCa tumors. However, the association between Western or Mediterranean dietary patterns and PCa was not clear.
Article
Oncology
Miguel F. Sanmamed, Inmaculada Rodriguez, Kurt A. Schalper, Carmen Onate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Perez-Gracia, Salvador Martin-Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero
Article
Oncology
N. V. Rajeshkumar, Prasanta Dutta, Shinichi Yabuuchi, Roeland F. de Wilde, Gary V. Martinez, Anne Le, Jurre J. Kamphorst, Joshua D. Rabinowitz, Sanjay K. Jain, Manuel Hidalgo, Chi V. Dang, Robert J. Gillies, Anirban Maitra
Article
Oncology
Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohorquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, Jose Baselga
CLINICAL CANCER RESEARCH
(2015)
Article
Oncology
Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B. Brachmann, Carla Heise, Daniel Pierce, Pedro P. Lopez-Casas, Camino Menendez, Josep Tabernero, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, Daniel D. Von Hoff
CLINICAL CANCER RESEARCH
(2015)
Article
Oncology
Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Joerg Kleeff, Bruno Sainz, Christopher Heeschen
CLINICAL CANCER RESEARCH
(2015)
Article
Gastroenterology & Hepatology
Bruno Sainz, Sonia Alcala, Elena Garcia, Yolanda Sanchez-Ripoll, Maria M. Azevedo, Michele Cioffi, Marianthi Tatari, Irene Miranda-Lorenzo, Manuel Hidalgo, Gonzalo Gomez-Lopez, Marta Canamero, Mert Erkan, Joerg Kleeff, Susana Garcia-Silva, Patricia Sancho, Patrick C. Hermann, Christopher Heeschen
Article
Gastroenterology & Hepatology
Michele Cioffi, Sara M. Trabulo, Yolanda Sanchez-Ripoll, Irene Miranda-Lorenzo, Enza Lonardo, Jorge Dorado, Catarina Reis Vieira, Juan Carlos Ramirez, Manuel Hidalgo, Alexandra Aicher, Stephan Hahn, Bruno Sainz, Christopher Heeschen
Article
Oncology
Analia Azaro, Jordi Rodon, Antonio Calles, Irene Brana, Manuel Hidalgo, Pedro P. Lopez-Casas, Manuel Munoz, Paul Westwood, Joel Miller, Brian A. Moser, Ute Ohnmacht, William Bumgardner, Karim A. Benhadji, Emiliano Calvo
INVESTIGATIONAL NEW DRUGS
(2015)
Article
Oncology
Antonio Cubillo, Jesus Rodriguez-Pascual, Fernando Lopez-Rios, Carlos Plaza, Elena Garcia, Rafael Alvarez, Emilio de Vicente, Yolanda Quijano, Ovidio Hernando, Carmen Rubio, Sofia Perea, Gema Sanchez, Manuel Hidalgo
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2016)
Article
Oncology
Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, Daniel W. Bowles
CLINICAL CANCER RESEARCH
(2015)
Editorial Material
Biochemistry & Molecular Biology
Joseph E. Grossman, Divya Vasudevan, Cailin E. Joyce, Manuel Hildago
Review
Oncology
Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo
Summary: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging cancer to treat. Chemotherapy has limited benefits and immunotherapy has made little progress. However, recent advances in understanding the tumor microenvironment and new approaches to immunotherapy have provided hope. Improvements in preclinical models, targeting the tumor microenvironment, and identifying biomarkers will likely lead to better selection of patients who could benefit from immunotherapy. Urgent research is needed to design effective combination trials to cure patients with PDAC.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong
Summary: This study reports exceptional responses observed in patients with pMMR/MSS colon and rectal cancer treated with neoadjuvant botensilimab (BOT) and balstilimab (BAL). The findings have important implications for clinical trial designs using neoadjuvant immunotherapy and potentially sparing patients chemotherapy.
Article
Biochemistry & Molecular Biology
Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong
Summary: Neoadjuvant botensilimab and balstilimab showed exceptional responses in patients with locally advanced mismatch repair proficient/microsatellite stable colon and rectal cancer. The observed rapid immune response pattern has not been previously described. Spatial biology analyses revealed the mechanism of action of botensilimab.
Article
Oncology
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A. Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M. Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J. Shields, Joseph E. Grossman, Xin Huang, Meggan Tammaro, Jean-Francois Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla
Summary: This study evaluates the clinical efficacy and safety of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma. The preclinical and clinical data suggest that this combination treatment has antitumor activity and tolerable toxicity, but does not meet the prespecified efficacy threshold.
CANCER RESEARCH COMMUNICATIONS
(2022)